Matinas BioPharma

📍 Bedminster, United States🗓 Founded 2011👥 35 employees💰 Last funded Aug 2013
Biotechnology Research🌐 matinasbiopharma.com
Website LinkedIn
Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2011
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Matinas BioPharma?
Matinas BioPharma has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Matinas BioPharma last raise funding?
The most recent investment in Matinas BioPharma recorded on gritt.io was in August 2013.
When was Matinas BioPharma founded?
Matinas BioPharma was founded in 2011.
What industry is Matinas BioPharma in?
Matinas BioPharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Matinas BioPharma based?
Matinas BioPharma is headquartered in Bedminster, United States.